George Yancopoulos
Tracked across 4 events · 33 articles · First seen May 19, 2025 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: George Yancopoulos is the co-Founder, Board co-Chair, President, and Chief Scientific Officer of Regeneron Pharmaceuticals, and the Innovator Award is named in his honor, reflecting his commitment to STEM.
May 15, 2026 · 10 articles
Business
Impact: George Yancopoulos, co-Chair, President, and Chief Scientific Officer at Regeneron Pharmaceuticals, highlighted the significance of Dupixent's approval as a new standard of care for young children with chronic spontaneous urticaria.
Apr 13, 2026 · 8 articles
Business
Impact: George Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron Pharmaceuticals, emphasized the significance of Dupixent's approvals and its role in treating type 2 inflammatory diseases.
Feb 24, 2026 · 8 articles
ERGEN INTELLIGENCE
Track George Yancopoulos live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard